Personalis, Inc. Common Stock (PSNL) is a publicly traded Healthcare sector company. As of May 21, 2026, PSNL trades at $8.00 with a market cap of $703.73M and a P/E ratio of -7.49. PSNL moved +12.78% today. Year to date, PSNL is -0.87%; over the trailing twelve months it is +60.28%. Its 52-week range spans $2.83 to $11.50. Analyst consensus is strong buy with an average price target of $10.46. Rallies surfaces PSNL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Personalis Reports 329% Clinical Test Surge and 239% MRD Revenue Growth: Personalis delivered a 329% year-over-year increase in clinical tests and grew biopharma MRD revenue by 239% while securing Medicare coverage for breast and lung cancer. The company ended the quarter with $240 million cash, plans to double its salesforce, reported a $23.8 million net loss and saw gross margins compress to 11%.
| Metric | Value |
|---|---|
| Price | $8.00 |
| Market Cap | $703.73M |
| P/E Ratio | -7.49 |
| EPS | $-1.02 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.50 |
| 52-Week Low | $2.83 |
| Volume | 16 |
| Avg Volume | 0 |
| Revenue (TTM) | $64.52M |
| Net Income | $-95.55M |
| Gross Margin | 13.72% |
7 analysts cover PSNL: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.46.